Journal Global Drugs and Therapeutics (ISSN 2733-256X)

All the work at Science Repository is licensed under a Creative Commons Attribution 4.0 International License. Authors at Science Repository retain copyright to their work and allow others to copy, distribute, transmit, and adapt their work, provided proper attribution is given.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. View License Deed | View Legal Code

For submission authors can directly submit manuscript to [email protected]


Manuscripts number will be provided to the corresponding author within 72 hours for the respective manuscript submitted.

  • 14 day review process with international peer-review standards
  • Timeline of processing from Submission to Publication is 30 days
  • Manuscript will be published within 7 days of acceptance


Will be updated soon

Editorial board

Peter Seville

Head of School of Pharmacy and Biomedical Sciences , Professor of Pharmaceutical sciences

School of Pharmacy and Biomedical Sciences , University of Central Lancashire

United Kingdom


Professor Peter Seville graduated with a Bachelor of Pharmacy degree from the Welsh School of Pharmacy, Cardiff, following which he undertook his pre-registration pharmacist placement at St Peter’s Hospital, Surrey. He then spent some time as a basic grade pharmacist at the Royal Free Hospital, London, before returning to Cardiff University to commence a PhD investigating the development of solution pressurised metered dose inhaler systems. Following a brief spell as a community pharmacy manager in Caerphilly, he returned once more to Cardiff to a postdoctoral research position investigating pulmonary delivery of non-viral gene therapies. Peter joined Aston University, Birmingham as a Lecturer, subsequently Senior Lecturer, in Pharmaceutics in 2002. He led the Inhalation Technology Research Team, published several original research papers and has a patent in the area of pulmonary drug delivery. Peter also served as a member of the Academy of Pharmaceutical Sciences Inhalation Focus Group steering committee, and co-organised a number of symposia and conferences in the area of inhalation science. Following a few years pursuing personal interests, Peter returned to academia, joining the University of Birmingham as Deputy Head of Pharmacy, developing a new integrated MPharm degree. Recently, Peter has been appointed Professor of Pharmaceutical Sciences and Head of the School of Pharmacy and Biomedical Sciences at the University of Central Lancashire. Peter has a long history of research in the development of inhalable formulations, and in particular expertise in the use of spray-drying technology to generate powders with enhanced aerosolisation properties.

Himangshu Sekhar Maji

Principal & Professor

Bengal School of Technology

Hooghly, India


Prof. Himangshu Sekhar Maji was graduated during 1995-99; post graduated during 2000-02 from Jadavpur University, and also awarded Ph.D. from Jadavpur University in 2010. Awarded Doctor of Philosophy (Pharmacy) by Jadavpur University, India in the year 2010; presently working as Principal & Professor (Pharmaceutical Analysis) in Bengal School of Technology, Hooghly.

Run Zhang


Australian Institute of Bioengineering and Nanotechnology

The University of Queensland



Dr. Run Zhang carried out his doctoral studies in the State Key Laboratory of Fine Chemicals at Dalian University of Technology, China. He moved to the Physics and Astronomy Department of Macquarie University as a postdoctoral research fellow immediately after finishing his PhD in July 2012. Then, he won a highly competitive Macquarie University Research Fellowship (MQRF) and took up this independent position in the Department of Chemistry and Biomolecular Science in January 2013. In January 2015, he was appointed as a visiting research fellow in Australian Institute of Bioengineering and Nanotechnology (AIBN), The University of Queensland (UQ). In December 2015, Dr Zhang was appointed as an adjunct associate professor in University of Science and Technology Liaoning, China. In February 2016, he re-located to AIBN, UQ to work on a research associate position. Dr Zhang is an expert in the field of synthetic and analytical chemistry, nanomaterial science, nano-/bio-interface (surface chemistry), and biophotonics. As an interdisciplinary scientist, he has made significant contributions in the respects of: i) development of a series of specific biosensors to probe important biomarkers in live systems; ii) fabricating functional nanomaterial for cancer early diagnosis and imaging guided tumour therapy; iii) inventing several chemosensors to detect the environmental pollutants; iv) engineering next generation nanotechnology for data security against forgery. Since 2014, Dr Zhang has voluntarily served as the editorial board and the reviewer for many international journals.

El Hassane Larhrib

Senior lecturer in Pharmaceutics

Department of Pharmacy

University of Huddersfield

United Kingdom


Dr. Larhrib was educated at the University of Sciences and Technology, Lille I and the faculty of Pharmacy, Lille II, France where he obtained an MSc Biochem, DU Pharm, DESS Pharm. Tech. and a certificate in Pharm. Chemistry. He moved to the UK to do a PhD in Pharmaceutical technology at Liverpool John Moores University, using high speed compaction simulator to fundamentally study the mechanism of compaction of pharmaceutical powders under the supervision of Dr. James Wells and Prof. Mike Rubinstein (1994-1998). Following his PhD, Dr Larhrib worked for 4 years (1998-2002) as Senior Research Fellow in Pharmaceutics at the Department of Pharmacy, King’s College London. He worked at Liverpool John Moores University as a Senior lecturer in Pharmaceutics for 6 years (2002-2007) before joining the industry; Solid Solution Limited, Liverpool (2007-2010). He was involved in cosmetic products development and manufacture. He moved to Medway school of Pharmacy before joining the University of Huddersfield as a Senior lecturer in Pharmaceutics in July 2011. Dr. Larhrib is a regular reviewer for many international Pharmaceutical journals and member of editorial board of journal of International Research in Medical and Pharmaceutical Sciences and British Journal of Pharmaceutical Research.

Christina Drenberg Guttke

Research Assistant Professor

Division of Pharmaceutics and Pharmaceutical Chemistry

The Ohio State University

Columbus, Ohio, United States


Dr. Drenberg is currently a Research Assistant Professor at The Ohio State University in the College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry. She studied biomedical sciences at the University of South Florida in her hometown of Tampa, FL and proceeded to earn her Ph.D. from the College of Medicine in Medical Sciences. She is passionate about identifying new treatment strategies for orphan diseases, like pediatric acute myeloid leukemia.

Farideh A Javid

Senior Lecturer in Pharmacology

Department of Pharmacy

University of Huddersfield

United Kingdom


Dr Farideh Javid is a Senior Lecturer in Pharmacology at the Department of Pharmacy, University of Huddersfield, UK. She developed the Pharmacology modules for the MPharm course at the University of Huddersfield for years 1, 2 and 3 and her on-going research programmes focus on identifying and investigating the mechanism of actions of novel drugs in cancer Pharmacology. Her ultimate aim is to develop novel drugs for cancer patients. She holds several patents as a result of her collaboration with industry.

Chandra P Sharma

Former Head of Biomedical Technology , Associate Dean - PhD Programme

Sree Chitra Tirunal Institute for Medical Science and Technology Kerala



Chandra P. Sharma is the Acting Head of Biomedical Technology Wing and Associate Dean - PhD Programme, Sree Chitra Tirunal Institute for Medical Science & Technology, Kerala, India, and has been the Head of the Biosurface Technology Division since 1980. His areas of expertise include: biomaterials science and engineering; polymeric and metallic micro/nano particles based delivery systems; and surface modification and tissue/blood compatibility of materials. Dr. Sharma has published over 325 research papers with over 6500 citations (Scopus) and has processed over 40 patents including in Canada, European Union, Japan and USA. He has served as guest editor and reviewer of several international journals and has edited books with Dr. Michael Szycher on Blood Compatible Materials and Devices, and on Biointegration of medical implant materials: Science and design, with Woodhead Publishing. His laboratory has completed leading research in the field.

Yong Zhang

University of North Carolina

United States

Alan David Goddard

Aston University

Birmingham, United Kingdom

Kaustuv Sahoo

Oklahoma State University

United States

Amit Rawat

Texas Tech University Health Sciences Center

Amarillo, United States

Qian Zhong

Stanford University

United States

Lijuan Cao

China Pharmaceutical University

Nanjing, China

Noha Mohamed Zaki Rayad

Taif University

Saudi Arabia

Zhenjia Wang

Assistant Professor

Department of Pharmaceutical Sciences

College of Pharmacy , Washington State University

United States

Xu Han

Chief Technology Officer

University of Miami

United States

Current Issue Volume 1, Issue 1

Isoabsorptive Point Method for Simultaneous Determination of Paracetamol and Orphenadrine Citrate in Their Combined Pharmaceutical Dosage Forms

Novel Composite Nanocarriers

Chemical Composition and Evaluation of the Antimicrobial Activity of the Of Illicium Verum and the Derivations of Protocatechuic Acid

How Phytocomponents May be Valuable Against Oxidative Stress in Brain Tissue?

The Levels of Perceived Emotional Abuse among Pakistani Husbands and Wives

Submit Manuscript

You can submit your manuscript at Science Repository. Authors submit manuscript files and metadata & can request for revision. Editors use the system to review submissions, assign to reviewers, and make and communicate decisions to accept, revise, transfer or reject manuscripts. Reviewers are invited to work on manuscripts, can accept or reject assignments.

For submission authors can directly submit manuscript to [email protected]

Manuscripts number will be provided to the corresponding author within 72 hours for the respective manuscript submitted.

  • 14 day review process with international peer-review standards
  • Timeline of processing from Submission to Publication is 30 days
  • Manuscript will be published within 7 days of acceptance

Publication Charges

Global Drugs and Therapeutics is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License".

In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.

The publication charges for Global Drugs and Therapeutics are £ (GBP) 1099.

Frequently Asked Questions (FAQs)

Why do we charge?

All articles published in Science Repository are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in Science Repository Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.

Our financial goals are to:

  • Maintain the portal for best experienece
  • Recover capitalization cost
  • Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development
  • Although we charge the minimum possible but we will reduce the publication-charge cost downward over time.

When should I pay?

Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.

*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.

Who will pay the APC (Article Processing Charges)?

Corresponding author or Co-authors has to make the payment on acceptance of the article.

How do I pay?

Authors or institutions can make payments by two modes as per their convenience.

  • Online Card payment

Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction gateway charges may be levied on the payee.

Do I have to pay if my manuscript is rejected?

No, Article processing charges will not be applicable for articles rejected by the Editorial office.

Can I be eligible for wavier on APC?

The waiver request will be considered on a case-by-case basis, and will be provided accordingly.

*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.

Withdrawal Charges

Please check our Refund Policy

Are reprints of my article included in the article processing charges (APCs)?

No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.

For more details you can refer to FAQs or contact us [email protected]


We are currently preparing the archive. Will be updated soon.